Third, the study did not include comprehensive data on the use of contemporary guideline-directed medical therapy for HF (e.g., SGLT2 inhibitors, sacubitril/valsartan), and the absence of these data may have affected the interpretation of HF-related outcomes. The gene discussed is SLC5A2; the disease is hydrops fetalis.